Acinetobacter baumannii ADC-25 OXA-23 OXA-66 (CDC & FDA AR Isolate Bank #0282), Bacteremia Model (IV Infection), LD90-100

  1. image
  2. image
CONTACT CUSTOMER SERVICE
  ADD TO FAVORITES
  ADD TO PANEL
OVERVIEW
DOCUMENTS/REFERENCES
RELATED SERVICES
RELATED PRODUCTS
BIOLOGICAL INFORMATION
BACKGROUND INFORMATION
This model assesses the efficacy of test articles for protection against a lethal infection. It may be used to evaluate small molecules, biologics, and vaccines.
SPECIES
Acinetobacter baumannii
STRAIN COMMON NAME
(AR Bank #0282)
ORGANISM
Gram-negative Bacteria
INCUBATION CONDITIONS
Aerobic
NOTABLE ANTIBIOTIC RESISTANCE GENE
OXA-23
GENOMIC ACCESSION NUMBER
SAMN04901672
SOURCE
STRAIN SOURCE
CDC & FDA AR Isolate Bank
STRAIN SOURCE ID
AR Bank #0282
ASSAY INFORMATION
ASSAY TYPE
In Vivo
TESTING INFORMATION
PROCEDURE SUMMARY
Groups of 10 BALB/c derived female mice weighing 18 ± 2 g are used. Each animal is inoculated with an intravenously administered LD90-100 dose (5.0 x 10⁸ CFU/mouse) of A. baumannii (AR Bank #0282) which is suspended in 0.1 mL PBS. Vehicle and/or test substances are then administered 1 and 13 hours later per the specification of the study design table. Mortality is recorded daily during the following 10 days. Prevention of mortality is recorded in percentage, and the significance is assessed by Fisher's exact test. The mean survival time is compared to the vehicle group with Student's t-test or ANOVA.
CRITERIA FOR SIGNIFICANCE
Mortality data is graphed with the Kaplan Meier Method and Significance is assessed with the Fisher's exact test.
TURNAROUND TIME
STANDARD
20 Days
CLINICAL RELEVANCE
THERAPEUTIC AREA
Infectious Disease
ADDITIONAL INFORMATION
BRAND
PDS
TESTING LOCATION
Taiwan - Taipei
OTHER INFORMATION
We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.

 

© Copyright 2026, Pharmacology Discovery Services – Privacy Policy | Cookie Notice | Cookie Preferences